Attached files
| file | filename |
|---|---|
| EX-10.3 - EX-10.3 - Finch Therapeutics Group, Inc. | d54314dex103.htm |
| S-1 - S-1 - Finch Therapeutics Group, Inc. | d54314ds1.htm |
| EX-21.1 - EX-21.1 - Finch Therapeutics Group, Inc. | d54314dex211.htm |
| EX-10.9 - EX-10.9 - Finch Therapeutics Group, Inc. | d54314dex109.htm |
| EX-10.8 - EX-10.8 - Finch Therapeutics Group, Inc. | d54314dex108.htm |
| EX-10.7 - EX-10.7 - Finch Therapeutics Group, Inc. | d54314dex107.htm |
| EX-10.6 - EX-10.6 - Finch Therapeutics Group, Inc. | d54314dex106.htm |
| EX-10.5 - EX-10.5 - Finch Therapeutics Group, Inc. | d54314dex105.htm |
| EX-10.4 - EX-10.4 - Finch Therapeutics Group, Inc. | d54314dex104.htm |
| EX-10.1 - EX-10.1 - Finch Therapeutics Group, Inc. | d54314dex101.htm |
| EX-4.1 - EX-4.1 - Finch Therapeutics Group, Inc. | d54314dex41.htm |
| EX-3.2 - EX-3.2 - Finch Therapeutics Group, Inc. | d54314dex32.htm |
| EX-3.1 - EX-3.1 - Finch Therapeutics Group, Inc. | d54314dex31.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement on Form S-1 of our report dated February 26, 2021 relating to the consolidated financial statements of Finch Therapeutics Group, Inc. and its subsidiaries. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
February 26, 2021